Neurol. praxi 2017; 18(Suppl.B)

Zaznìlo na IV. konferenci Neurologie pro praxi v Plzni

Published: April 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zaznìlo na IV. konferenci Neurologie pro praxi v Plzni. Neurol. praxi. 2017;18(Suppl.B - Zaznìlo na IV. konferenci Neurolo):.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Cox D, Stone J. Managing self-injection difficulties in pati-ents with relapsing-remitting multiple sclerosis. J Neurosci Nurs. 2006 Jun; 38(3): 167-171. Go to original source... Go to PubMed...
    2. Chen C, Baraban E, Stuchiner T, et al. Evaluating medication adherence to disease-modifying therapy (DMT) and associated factors using data from the Pacific Northwest Multiple Sclerosis Registry. Mult Scler. 2013; 19(Suppl. 11): 479.
    3. Stuchiner T, Chen C, Baraban E, Cohan S. Medication adherence and the impact of oral medications: a study from the pacific northwest multiple sclerosis registry. Mult Scler. 2015; 23(Suppl. 11): 103-104.
    4. ##
    5. Ceny a úhrady Lemtrada. www.sukl.cz
    6. SPC Lemtrada. www.sukl.cz
    7. Coles AJ, Boyko AN, Cohen JA, et al. on behalf of the CARE-MS I Investigators. Alemtuzumab provides durable improvements in clinical outcomes in treatment-naive patients with active relapsing-remitting multiple sclerosis over 6 years in the absence of continuous treatment (CARE-MS I). ECTRIMS Online Library. Coles A. Sep 16, 2016; 147055.
    8. Fox EJ, Alroughani R, Brassat D, et al. on behalf of the CARE-MS II Investigators. Efficacy of alemtuzumab is durable over 6 years in patients with active relapsing-remitting multiple sclerosis and an inadequate response to prior therapy in the absence of continuous treatment (CARE-MS II). ECTRIMS Online Library. Sep 16, 2016; 145834. Go to original source...
    9. Traboulsee A, Barnett M, Comi G, et al. on behalf of the CARE-MS I and CARE-MS II Investigators. Alemtuzumab durably slows brain volume loss over 6 years in the absence of continuous treatment in patients with active RRMS who were treatment-naive (CARE-MS I) or had an inadequate response to prior therapy (CARE-MS II). ECTRIMS Online Library. Traboulsee A. Sep 16, 2016; 145864. Go to original source...
    10. Dayan C, Cuker A, LaGnake C, et al. on behalf of the CARE-MS Investigators. Autoimmunity in patients treated With Alemtuzumab for relapsing-remitting multiple sclerosis: 5-Year follow-up of the CARE-MS studies. ECTRIMS Online Library. Vermersch P. Sep 16, 2016; 147015.
    11. ##
    12. Warnke C, Meyer zu Hörste G, Hartung HP, et al. Review of teriflunomide and its potential in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat. 2009; 5: 333-340. Go to original source...
    13. O'Connor P, Wolinsky JS, Confavreux C, et al. TEMSO Trial Group. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011; 365(14): 1293-1303. Go to original source... Go to PubMed...
    14. Miller AE, Macdonell R, Comi G, et al. Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study. J Neurol. 2014; 261(9): 1781-1788. Go to original source... Go to PubMed...
    15. Wolinsky JS, Narayana PA, Nelson F, et al. Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. Mult Scler. 2013; 19(10): 1310-1319. Go to original source... Go to PubMed...
    16. Vermersch P, Czlonkowska A, Grimaldi LM, et al. TENERE Trial Group. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler. 2014; 20(6): 705-716. Go to original source... Go to PubMed...
    17. Miller AE, Wolinsky JS, Kappos L, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014; 13(10): 977-986. Go to original source...
    18. Freedman M. Long-term safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis in the TEMSO extension trial. ECTRIMS Online Library. Freedman M. Oct 3, 2013: 34024. Go to original source...
    19. Kappos L, Freedman MS, Comi G, et al. Teriflunomide efficacy on annualized relapse rate and expanded disability status scale scores: 2.5-year follow-up in the TOWER extension study in patients with relapsing MS. ECTRIMS Online Library. Kappos L. Oct 9, 2015: 115988.
    20. Wolinsky JS, Freedman MS, Thangavelu K, et al. Efficacy of teriflunomide treatment in achieving no evidence of disease activity in the TEMSO long-term extension study. ECTRIMS Online Library. Wolinsky JS. Oct 9, 2015: 115858.
    21. Leist T. Pooled safety data from three placebo-controlled teriflunomide studies. ECTRIMS Online Library. Leist T. Oct 3, 2013: 34113.
    22. SPC Aubagio. www.sukl.cz
    23. ##
    24. Kirby S, Sadler RM. Injury and death as a result of seizures. Epilepsia. 1995; 36(1): 25-28. Go to original source... Go to PubMed...
    25. Buck D, Baker GA, Jacoby A, et al. Patients' experiences of injury as a result of epilepsy. Epilepsia. 1997; 38(4): 439-444. Go to original source... Go to PubMed...
    26. Vestergaard P. Epilepsy, osteoporosis and fracture risk - a meta-analysis. Acta Neurol Scand. 2005; 112(5): 277-286. Go to original source... Go to PubMed...
    27. Nguyen R, Téllez Zenteno JF. Injuries in epilepsy: a review of its prevalence, risk factors, type of injuries and prevention. Neurol Int. 2009; 1(1): e20. Go to original source... Go to PubMed...
    28. van den Broek M, Beghi E; RESt-1 Group. Accidents in patients with epilepsy: types, circumstances, and complications: a European cohort study. Epilepsia. 2004; 45(6): 667-672. Go to original source...
    29. Hitiris N, Suratman S, Kelly K, et al. Sudden unexpected death in epilepsy: a search for risk factors. Epilepsy Behav. 2007; 10(1): 138-141. Go to original source...
    30. Nashef L, Annegers JF, Brown SW. Introduction and overview. Sudden unexpected death in epilepsy. Epilepsia. 1997; 38(Suppl. 11): S1-S2. Go to original source...
    31. Hesdorffer DC, Tomson T, Benn E, et al. Combined analysis of risk factors for SUDEP. Epilepsia. 2011; 52(6): 1150-1159. Go to original source...
    32. Thurman DJ, Hesdorffer DC, French JA. Sudden unexpected death in epilepsy: assessing the public health burden. Epilepsia. 2014; 55(10): 1479-1485. Go to original source...
    33. Devinsky O. Sudden, unexpected death in epilepsy. NEJM. 2011; 365: 1801-1811. Go to original source... Go to PubMed...
    34. Ryvlin P, Nashef L, Lhatoo SD, et al. Incidence and mechanisms of cardiorespiratory arrests in epilepsy monitoring units (MORTEMUS): a retrospective study. Lancet Neurol 2013; 12: 966-977. Go to original source...
    35. Seyal M, Hardin KA, Bateman LM. Postictal generalized EEG suppression is linked to seizure-associated respiratory dysfunction but not postictal apnea. Epilepsia. 2012; 53(5): 825-831. Go to original source...
    36. Tao JX, Yung I, Lee A, et al. Tonic phase of a generalized convulsive seizure is an independent predictor of postictal generalized EEG suppression. Epilepsia. 2013; 54: 858-865. Go to original source...
    37. Xu Z, Ayyappan S, Seneviratne U. Sudden unexpected death in epilepsy (SUDEP): what do patients think? Epilepsy Behav. 2015; 42: 29-34. Go to original source...
    38. SPC Fycompa. www.sukl.cz

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.